Eduardo Solsona

Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated With Bacillus Calmette-Guerin: The CUETO Scoring Model

J.M. Fernández Gómez, Rosário Madero, Eduardo Solsona et al. · The Journal of Urology · 2009 · 655 citations · Full text

Medicine, Oncology, Urology +9

Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial

Abdel-Rahmène Azzouzi, S. Vincendeau, Éric Barret et al. · The Lancet Oncology · 2016 · 330 citations

Medicine, Oncology, Pharmacology +15

Prognostic Factors in Patients with Non–Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: Multivariate Analysis of Data from Four Randomized CUETO Trials

J.M. Fernández Gómez, Eduardo Solsona, Miguel Unda et al. · European Urology · 2007 · 257 citations · Full text

Medicine, Oncology, Urology +6

A Multicentre, Randomised Prospective Trial Comparing Three Intravesical Adjuvant Therapies for Intermediate-Risk Superficial Bladder Cancer: Low-Dose Bacillus Calmette-Guerin (27 mg) versus Very Low-Dose Bacillus Calmette-Guerin (13.5 mg) versus Mitomycin C

Antonio Ojea, José Luís Nogueira, Eduardo Solsona et al. · European Urology · 2007 · 211 citations

Medicine, Oncology, Urology +10

HAS A 3-FOLD DECREASED DOSE OF BACILLUS CALMETTE-GUERIN THE SAME EFFICACY AGAINST RECURRENCES AND PROGRESSION OF T1G3 AND TIS BLADDER TUMORS THAN THE STANDARD DOSE? RESULTS OF A PROSPECTIVE RANDOMIZED TRIAL

J A Martínez-Piñeiro, Luis Martínez‐Piñeiro, Eduardo Solsona et al. · The Journal of Urology · 2005 · 198 citations

Medicine, Oncology, Urology +10